Michael Wiederhorn
Stock Analyst at Oppenheimer
(4.74)
# 645
Out of 4,442 analysts
1155
Total ratings
58.5%
Success rate
10.9%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACS PACS Group | Rated: Buy | $42 → $48 | $37.37 | +28.45% | 5 | May 13, 2026 | |
| PNTG The Pennant Group | Maintained: Buy | $40 | $34.23 | +16.86% | 18 | May 8, 2026 | |
| GRDN Guardian Pharmacy Services | Maintained: Buy | $43 | $39.19 | +9.72% | 7 | May 7, 2026 | |
| ADUS Addus HomeCare | Rated: Buy | $155 | $96.09 | +61.31% | 113 | May 6, 2026 | |
| HUM Humana | Maintained: Buy | $250 → $260 | $359.13 | -27.60% | 79 | Apr 30, 2026 | |
| CNC Centene | Rated: Buy | $45 → $58 | $63.14 | -8.14% | 163 | Apr 29, 2026 | |
| HCA HCA Healthcare | Rated: Buy | $520 | $386.92 | +34.39% | 95 | Apr 27, 2026 | |
| CYH Community Health Systems | Maintained: Buy | $4 | $3.08 | +29.87% | 120 | Apr 23, 2026 | |
| UNH UnitedHealth Group | Rated: Buy | $385 → $405 | $409.25 | -1.04% | 87 | Apr 22, 2026 | |
| CHE Chemed | Maintained: Buy | $500 | $444.11 | +12.58% | 117 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $158.89 | - | 86 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.80 | - | 12 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $7 | $7.69 | -8.97% | 30 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $13.19 | - | 71 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $365 | $283.08 | +28.94% | 74 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $101.57 | n/a | 17 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.0001 | n/a | 6 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $42.91 | n/a | 1 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $395.10 | n/a | 48 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $0.000001 | n/a | 6 | Aug 19, 2014 |
PACS Group
May 13, 2026
Rated: Buy
Price Target: $42 → $48
Current: $37.37
Upside: +28.45%
The Pennant Group
May 8, 2026
Maintained: Buy
Price Target: $40
Current: $34.23
Upside: +16.86%
Guardian Pharmacy Services
May 7, 2026
Maintained: Buy
Price Target: $43
Current: $39.19
Upside: +9.72%
Addus HomeCare
May 6, 2026
Rated: Buy
Price Target: $155
Current: $96.09
Upside: +61.31%
Humana
Apr 30, 2026
Maintained: Buy
Price Target: $250 → $260
Current: $359.13
Upside: -27.60%
Centene
Apr 29, 2026
Rated: Buy
Price Target: $45 → $58
Current: $63.14
Upside: -8.14%
HCA Healthcare
Apr 27, 2026
Rated: Buy
Price Target: $520
Current: $386.92
Upside: +34.39%
Community Health Systems
Apr 23, 2026
Maintained: Buy
Price Target: $4
Current: $3.08
Upside: +29.87%
UnitedHealth Group
Apr 22, 2026
Rated: Buy
Price Target: $385 → $405
Current: $409.25
Upside: -1.04%
Chemed
Mar 31, 2026
Maintained: Buy
Price Target: $500
Current: $444.11
Upside: +12.58%
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $158.89
Upside: -
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $4.80
Upside: -
Mar 3, 2026
Maintained: Buy
Price Target: $12 → $7
Current: $7.69
Upside: -8.97%
Nov 19, 2025
Maintained: Hold
Price Target: n/a
Current: $13.19
Upside: -
Oct 31, 2025
Maintained: Buy
Price Target: $365
Current: $283.08
Upside: +28.94%
Aug 9, 2024
Maintained: Hold
Price Target: n/a
Current: $101.57
Upside: n/a
Mar 2, 2023
Maintained: Buy
Price Target: $3
Current: $0.0001
Upside: n/a
Feb 9, 2018
Reiterated: Buy
Price Target: $35
Current: $42.91
Upside: n/a
Jun 7, 2017
Rated: Hold
Price Target: n/a
Current: $395.10
Upside: n/a
Aug 19, 2014
Rated: Buy
Price Target: $7
Current: $0.000001
Upside: n/a